A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

Trial Profile

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Enasidenib (Primary) ; Ivosidenib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 Oct 2018.
    • 14 Feb 2018 According to an Agios Pharmaceuticals media release, updated data from this ongoing study has been submitted to 2018 American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 12 Dec 2017 Initial results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top